skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
Home » UK Shares » Three Quick Facts » Three Quick Facts: Smiths Group, Stagecoach Group and Open Orphan

Three things you need to know in the financial markets this morning from investment writer, Tony Cross.

Smiths Group

Interim results are out from Smiths Group [LON:SMIN] this morning, covering the six month period to January 31st. Revenues may be off by 5%, but with a 33% uptick in cash conversion, shareholders are being rewarded with a modest uplift in dividend payments. The company anticipates a further improvement in performance for the second half of the year and subject to no further disruption, will be on target to meet full year expectations.

Stagecoach Group

There’s a trading statement out from Stagecoach Group [LON:SGC], ahead of the May 1st financial year end. The company remains upbeat about the outlook for the business once COVID restrictions are eased and there’s no apparent concern that the stay at home mindset instilled by a series of lockdowns will have any lasting effect. Government support for the bus network remains in place until social distancing on transport is no longer deemed necessary and there’s confidence that structures will be in place to manage the transition beyond this – it seems inevitable that demand won’t be back to historical levels overnight.

Subscribe for more stories like this, 8am weekdays - for free!

Open Orphan

Open Orphan [LON:ORPH], the AIM listed pharmaceuticals clinical research organisation, has this morning announced that one of its subsidiaries has entered into a contract with a US biotech company to run a human challenge trial for an RSV – respiratory syncytial virus – therapy. RSV is one of the leading causes of hospitalisation of young children across the world and there’s concern that it could also worsen the impact of COVID-19. Revenues from the £7.5m contract will largely be recognised in the current financial year.

Sign up for three quick facts and more with our Free Daily Digest newsletter, every weekday morning.

This article is not investment advice. Investors should do their own research or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we follow most closely. They represent significant growth stories in our view. Our in-depth reports detail why we like them.


This Post Has One Comment

  1. Any views on TRMR prior to their proposed listing on Nazdeq on the 2nd Quarter of this year would be much appreciated in your AIM column at some stage thanks. Ricky

Comments are closed.

Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top